Why the study?
Prader-Willi syndrome (PWS) creates a metabolic context that differs from non-syndromic obesity (NSO), and whether PWS confers a uniformly more atherogenic lipid phenotype in pediatric patients remains uncertain.
Population
Pediatric patients with Prader-Willi syndrome and non-syndromic obesity
Comparison
Pediatric Prader-Willi syndrome vs non-syndromic obesity
Design
Critical narrative review
Answers are grounded in this paper and cite their sources.
Standard lipid profiles remain the clinical benchmark in pediatric Prader-Willi syndrome; leaves open whether unreplicated lipidomic differences merit prospective validation.
Prader–Willi syndrome (PWS) combines genetically determined hyperphagia, altered body composition, growth hormone (GH) axis abnormalities, and progressive obesity, creating a metabolic context that differs from non-syndromic obesity (NSO). Whether PWS confers a uniformly more atherogenic lipid phenotype remains uncertain. This critical narrative review synthesizes pediatric evidence on conventional lipids, lipidomic remodeling, and their relationships with adiposity, insulin sensitivity, inflammation, body composition, genotype, and recombinant human GH (rhGH) exposure. More adverse conventional lipid profiles have been reported mainly in cohorts without rigorous matching for adiposity or body composition; these findings cannot be assumed to represent an independent syndrome effect. In contrast, a GH-naive cohort with similar BMI to NSO controls showed markedly higher lipoprotein(a) in PWS but broadly similar triglyceride, HDL-C, and LDL-C concentrations. Lipidomic evidence is more limited: a single pediatric discovery cohort reported lower total phosphatidylcholine and lysophosphatidylcholine concentrations in PWS than in NSO and normal-weight controls, together with exploratory PWS-specific associations between selected phospholipid species, BMI, and gut microbial taxa. These molecular findings have not yet been independently replicated and should not be interpreted as a validated diagnostic or prognostic signature. Overall, conventional lipid assessment remains the clinical standard and should be interpreted alongside adiposity, lean mass, pubertal stage, and rhGH exposure. Lipidomics currently provides mechanistic and hypothesis-generating information rather than a PWS-specific clinical risk-stratification tool.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: